Short Communication

Generation of the Human Metabolite Piceatannol from the Anticancer-Preventive Agent Resveratrol by Bacterial Cytochrome P450 BM3S

Received January 1, 2009; accepted February 18, 2009

ABSTRACT:

In recent studies, the wild-type and mutant forms of cytochrome P450 (P450) BM3 (CYP102A1) from Bacillus megaterium were found to metabolize various drugs through reactions similar to those catalyzed by human P450 enzymes. Therefore, it was suggested that CYP102A1 can be used to produce large quantities of the metabolites of human P450-catalyzed reactions. trans-Resveratrol (3,4’-5-trihydroxystilbene), an anticancer-preventive agent, is oxidized by human P450 1A2 to produce two major metabolites, piceatannol (3,5,3’-4’-tetrahydroxystilbene) and another hydroxylated product. In this report, we show that the oxidation of trans-resveratrol, a human P450 1A2 substrate, is catalyzed by wild-type and a set of CYP102A1 mutants. One major hydroxylated product, piceatannol, was produced as a result of the hydroxylation reaction. Other hydroxylated products were not produced. Piceatannol formation was confirmed by high-performance liquid chromatography and gas chromatograph-mass spectrometry by comparing the metabolite with the authentic piceatannol compound. These results demonstrate that CYP102A1 mutants can be used to produce piceatannol, a human metabolite of resveratrol.

Resveratrol (3,4’,5-trihydroxystilbene) (Fig. 1) is a phytoalexin found in a wide variety of dietary sources including grapes, plums, and peanuts. It exhibits pleiotropic health-beneficial effects including antioxidant, anti-inflammatory, cardioprotective, and antitumor activities (Athar et al., 2007; Kundu and Surh, 2008; Pirola and Fröjdö, 2008). Currently, numerous preclinical findings suggest resveratrol as a promising part of nature’s arsenal for cancer prevention and treatment. As a potential anticancer agent, resveratrol has been shown to inhibit or retard the growth of various cancer cells in culture and implanted tumors in vivo. The compound significantly inhibits experimental tumorigenesis in a wide range of animal models. The biological activities of resveratrol are found to relate to its ability to modulate various targets and signaling pathways. Resveratrol exists as cis- and trans-isomers. trans-Resveratrol is the preferred steric form and is relatively stable.

Piceatannol (3,5,3’,4’-tetrahydroxystilbene) (Fig. 1) is a polyphenol found in grapes and other plants. It is known as a protein kinase inhibitor that modifies multiple cellular targets, exerting immunosuppressive and antitumorigenic activities in several cell lines. Piceatannol has been shown to exert various pharmacological effects on immune and cancer cells (Kim et al., 2008b and references therein). In humans, piceatannol is produced as a major metabolite of resveratrol by CYP1B1 and CYP1A2 (Potter et al., 2002; Piver et al., 2004). In addition, the metabolism of trans-resveratrol into two major metabolites, piceatannol and another tetrahydroxystilbene, is catalyzed by recombinant human CYP1A1, CYP1A2, and CYP1B1 (Piver et al., 2004). It is also known that trans-resveratrol can inhibit reactions catalyzed by human CYP1A1 and CYP1A2 (Chun et al., 1999).

If prodrugs are converted to biologically “active metabolites” by human liver cytochromes P450 (P450s) during the drug development process (Johnson et al., 2004), large quantities of the pure metabolites are required to understand the drug’s efficacy, toxic effect, and pharmacokinetics. Because the pure metabolites may be difficult to synthesize, an alternative is to use P450s to generate the metabolites of drugs or drug candidates. Although hepatic microsomes can be a source of human P450s, their limited availability makes their use in preparative-scale metabolite synthesis impractical. Some human enzymes can also be obtained by expression in recombinant hosts (Yun et al., 2006). Metabolite preparation has been demonstrated using human P450s expressed in Escherichia coli and in insect cells (Parikh et al., 1997; Rushmore et al., 2000; Vail et al., 2005), but these systems are costly and have low productivities due to limited stabilities and slow reaction rates (Guengerich et al., 1996). An alternative approach to preparing the human metabolites is to use an engineered bacterial P450 that has the desired catalytic activities.

Several mutants of Bacillus megaterium P450 BM3 (CYP102A1) generated through rational design or directed evolution could oxidize several human P450 substrates to produce authentic metabolites with higher activities (Otey et al., 2005; Yun et al., 2007 and references therein; Kim et al., 2008a; Stjernschantz et al., 2008). These recent results demonstrate that CYP102A1 mutants can be used to produce piceatannol, a human metabolite of resveratrol.
advances suggest that CYP102A1 can be developed as biocatalysts for drug discovery and synthesis (Bernhardt, 2006; Di Nardo et al., 2007). Very recently, it was reported that some selected mutations enabled the CYP102A1 enzyme to catalyze O-deethylation and 3-hydroxylation of 7-ethoxycoumarin, which are the same reactions catalyzed by human P450s (Kim et al., 2008a).

In this study, we tested whether CYP102A1 mutants could be used to produce piceatannol, the major human metabolite of trans-resveratrol. Piceatannol is more expensive than trans-resveratrol, its sub-strate. Some of the tested mutations enabled the CYP102A1 enzyme to catalyze the hydroxylation of trans-resveratrol to generate its human metabolite, piceatannol.

Materials and Methods

Chemicals. trans-Resveratrol, piceatannol, and NADPH were purchased from Sigma-Aldrich (St. Louis, MO). Other chemicals were of the highest grade commercially available.

Construction of BM3 Mutants by Site-Directed Mutagenesis. Seventeen different site-directed mutants of CYP102A1 were prepared as described previously (Kim et al., 2008a and references therein). The CYP102A1 mutants used in this study were selected based on earlier work showing their increased catalytic activity toward several human substrates. Each mutant bears the amino acid substitution(s) relative to wild-type CYP102A1, as summarized at Table 1 (Kim et al., 2008a).

Expression and Purification of CYP102A1 Mutants. Wild-type and mutants of CYP102A1 were expressed in E. coli and purified as described previously (Kim et al., 2008a). The CYP102A1 concentrations were determined from CO-difference spectra as described by Omura and Sato (1964) using $e = 91 \text{ mM/cm}$. For all of the wild-type and mutated enzymes, a typical culture yielded 300 to 700 nM P450. The expression level of CYP102A1 wild-type and mutants was typically in the range of 1.0 to 2.0 nmol P450/mg cytosolic protein.

Hydroxylation of trans-Resveratrol. Typical steady-state reactions for the trans-resveratrol hydroxylation included 50 pmol of CYP102A1 in 0.25 ml of 100 mM potassium phosphate buffer (pH 7.4) containing a final concentration of 100 $\mu$M trans-resveratrol. To determine the kinetic parameters of several CYP102A1 mutants, we used 2 to 500 $\mu$M trans-resveratrol. An aliquot of a NADPH-generating system was used to initiate reactions (final concentrations: 10 mM glucose 6-phosphate, 0.5 mM NADP+, and 1 IU yeast glucose 6-phosphate per ml). A stock solution of trans-resveratrol (20 mM) was prepared in dimethyl sulfoxide and diluted into the enzyme reactions with a final organic solvent concentration of $<1\% (v/v)$. The reaction mixtures (final volume of 0.25 ml) were incubated for 10 min at 37°C and terminated with 0.5 ml of ice-cold ethyl acetate. After centrifugation, the reaction mixture, organic phases were evaporated under a nitrogen gas. The product formation was analyzed by high-performance liquid chromatography (HPLC) as described previously (Piver et al., 2004). Samples (30 µl) were injected onto a Gemini C$_{18}$ column (4.6 mm $\times$ 150 mm, 5 µm; Phenomenex, Torrance, CA). The mobile phase A was water containing 0.5% acetic acid/acetonitrile (95.5, v/v); the mobile phase B was acetonitrile/0.5% acetic acid (95.5, v/v); the mobile phase A/B (75:25, v/v) was delivered at a flow rate of 1 ml/min by a gradient pump (LC-20AD; Shimadzu, Kyoto, Japan). Eluates were detected by UV at 320 nm.

To determine the total turnover numbers (TTNs) of several CYP102A1 mutants, 100 $\mu$M trans-resveratrol was used. The reaction was initiated by the addition of the NADPH-generating system, incubated for 1 and 2 h at 30°C. The formation rate of piceatannol was determined by HPLC as described above.

The kinetic parameters ($K_m$ and $k_{cat}$) were determined using nonlinear regression analysis with GraphPad Prism software (GraphPad, Software Inc., San Diego, CA). The data were fit to the standard Michaelis-Menten equation: $v = k_{cat}[E][S]/([S] + K_m)$, where the velocity of the reaction is a function of the turnover ($k_{cat}$), which is the rate-limiting step, the enzyme concentration ([E]), substrate concentration ([S]), and the Michaelis constant ($K_m$).

Gas Chromatograph-Mass Spectrometry Analysis. For the identification of the trans-resveratrol metabolite produced by the CYP102A1 mutants, the gas chromatograph-mass spectrometry (GC-MS) analysis compared the GC-profile and fragmentation patterns of the authentic compounds, piceatannol and trans-resveratrol. The oxidation reaction of trans-resveratrol by CYP102A1 mutants was done as described above. The aqueous samples were extracted with ethyl acetate. After centrifugation, the organic phase, standard trans-resveratrol, and authentic piceatannol solution (10 nM in ethanol) were each dried under nitrogen. Then trimethylsilyl derivatives were prepared as follows: 100 µl of a solution of N,O-bis(trimethylsilyl)trifluoroacetamide/trimethylchlorosilane (99:1, v/v) (Supelco, Bellefonte, PA) was added to the dry residue, and the mixture was left for 60 min at 60°C.

GC-MS analysis was performed on a GC-2010 gas chromatograph (Shimadzu) with an Rtx-5 column (5% diphenyl/95% dimethyl polysiloxane capillary column) (30 m $\times$ 0.32 mm i.d. $\times$ 0.25 µm film thickness). The injector temperature was 250°C. The derivatized samples of resveratrol and piceatannol were separated by GC under GC oven conditions of 60°C for 5 min, followed by an increase of 50°C for min $^{-1}$ up to 200°C, and then 2°C for min $^{-1}$ to 300°C. The gas chromatography was combined with a GCMS-QP2010 Shimazu mass spectrometer operating in electron ionization mode (70 eV) (Piver et al., 2004).

Results and Discussion

Oxidation of trans-Resveratrol by P450 BM3 Wild-Type and Its Mutants. We examined whether CYP102A1 can oxidize trans-resveratrol. First, the ability of wild-type and a set of P450 BM3 mutants to oxidize trans-resveratrol was measured at a fixed substrate concentration (100 µM). The metabolites were analyzed by HPLC and compared with those of human CYP1A2 (Table 1; Fig. 2). Whereas human CYP1A2 oxidized resveratrol to produce two major metabolites, CYP102A1 mutants produced only one major metabolite. In the case of the human metabolites, one is piceatannol and the other is also hydroxylated product, as reported previously (Piver et al., 2004). Wild-type and catalytically active mutants of CYP102A1 produced only one major product, which had a retention time that exactly matched the piceatannol standard, but not the other hydroxylated product. The turnover numbers for the entire set of the 17 mutants for the trans-resveratrol oxidation (piceatannol formation) varied over a
CYP102A1 wild-type showed a much lower catalytic activity (0.22 min$^{-1}$) (Table 1). Mutants #1 through #7 did not show apparent activities (0.03 min$^{-1}$). Mutants #8 through #17 showed higher activities than that of CYP102A1 wild-type. In the case of mutant #13, its turnover number (4.0 min$^{-1}$) was 18-fold higher than that of wild-type. The identities of the major metabolite and substrate were verified by comparing the results of HPLC (Fig. 2) and GC-MS (Supplemental Data Figs. S1 and S2) with standard compounds.

The production of piceatannol by CYP102A1 mutants was confirmed by GC-MS analysis after derivatization of the reaction mixture. The retention time and fragmentation pattern of the CYP102A1 metabolite were exactly matched to those of the piceatannol standard. 

**Fig. 2.** HPLC chromatograms of resveratrol metabolites produced by CYP102A1 mutants (C; mutants #10, #13, #14, and #15) and human CYP1A2 (B). Peaks were identified by comparing the retention times with those of standards, authentic piceatannol, and resveratrol (A). The peaks of the substrate and two major products (piceatannol and other hydroxylated product) are indicated. UV absorbance was monitored at 320 nm.

<table>
<thead>
<tr>
<th>Enzyme Mutated Amino Acid Residues</th>
<th>Piceatannol (nmol product/min/nmol P450)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type</td>
<td>F87A</td>
</tr>
<tr>
<td>#1 A264G</td>
<td>0.021 ± 0.001</td>
</tr>
<tr>
<td>#2 F87A/A264G</td>
<td>N.D.</td>
</tr>
<tr>
<td>#3 R47L/F87A</td>
<td>N.D.</td>
</tr>
<tr>
<td>#4 R47L/F87A/A264G</td>
<td>N.D.</td>
</tr>
<tr>
<td>#5 R47L/F87A/F87A/A264G</td>
<td>N.D.</td>
</tr>
<tr>
<td>#6 A74G/F87V/L188Q</td>
<td>1.1 ± 0.1</td>
</tr>
<tr>
<td>#7 R47L/L86I/L188Q</td>
<td>0.24 ± 0.01</td>
</tr>
<tr>
<td>#8 R47L/F87V/L188Q</td>
<td>1.6 ± 0.1</td>
</tr>
<tr>
<td>#9 R47L/L86I/L188Q/E267V</td>
<td>0.64 ± 0.03</td>
</tr>
<tr>
<td>#10 R47L/F87V/L188Q/E267V</td>
<td>0.33 ± 0.03</td>
</tr>
<tr>
<td>#11 R47L/L86I/L188Q/E267V</td>
<td>4.0 ± 0.1</td>
</tr>
<tr>
<td>#12 R47L/F87V/E143G/L188Q/E267V</td>
<td>1.3 ± 0.1</td>
</tr>
<tr>
<td>#13 R47L/E64G/F87V/E143G/L188Q/E267V</td>
<td>1.9 ± 0.3</td>
</tr>
<tr>
<td>#14 R47L/F81I/F87V/E143G/L188Q/E267V</td>
<td>0.97 ± 0.1</td>
</tr>
<tr>
<td>#15 R47L/E64G/F81I/F87V/E143G/L188Q/E267V</td>
<td>1.8 ± 0.1</td>
</tr>
</tbody>
</table>

N.D. not detectable (the rate of product formation was less than 0.001 nmol product/min/nmol P450).

**Kinetic Parameters of Resveratrol Oxidation by CYP102A1 Mutants.** Four high-activity and three low-activity mutants were identified.
chosen and used to measure kinetic parameters for the 3'-hydroxylation of resveratrol (Table 2). Some mutants of CYP102A1 did not show any or appreciable activities to determine reliable kinetic parameters (Table 1). Only mutant #13 showed significantly elevated \( k_{cat} \) values for the 3'-hydroxylation reaction, which had the highest \( k_{cat} \) values of 6.7 min\(^{-1}\). Mutant #11 showed values of only 0.12 min\(^{-1}\) The overall range of \( K_m \) values varied from 2.7 to 66 \( \mu \)M. The mutants displayed 56- and 24-fold variations in \( k_{cat} \) and \( K_m \) values for the 3'-hydroxylation reactions, respectively (Table 2). The catalytic efficiencies (\( k_{cat}/K_m \)) varied from 190-fold. In the case of human CYP1A2, the usual kinetic parameters could not be determined.

When the TTNs (mole product/mole catalyst) of the CYP102A1 mutants were determined, the overall range varied from 7 to 97 (Supplemental Data Fig. S4). Mutant #13 showed the highest activity, which was approximately 10-fold higher than that of human CYP1A2 with a 1-h incubation. Meanwhile, the wild-type CYP102A1 enzyme did not show any catalytic activity toward resveratrol (<1.0 nmol product/nmol P450). After the reaction mixtures were incubated for 1 and 2 h, the amount of the metabolite, piceatannol, was measured by HPLC. When the incubation was performed for 2 h, the overall activity increased slightly compared with that of the 1-h incubation.

This result seems due to the instability of the enzymes, inhibition of the P450 enzymes by the metabolite, or instability of the metabolite. In the case of human CYP1A2, no product remained after a 2-h incubation, although some amount of the product was shown after 1 h.

### Stability of CYP102A1 Mutants Measured by CO-Difference Spectra

It is known that the metabolite of resveratrol is a potent inhibitor against human P450s, CYP1A1, CYP1A2, and CYP1B1 (Chun et al., 1999, 2001). Resveratrol acts as a substrate and inhibitor to human CYP1A2 at the same time (Piver et al., 2004; Fairman et al., 2005). It is interesting to note that piceatannol, the major metabolite of resveratrol, is known as a potent inhibitor of human CYP1A2 (Mikstacka et al., 2006). Although mutant #10 showed moderately high activity, its stability was quite different from that of mutant #13. After a 30-min incubation, more than 70% of mutant #10 was still intact, although more than 90% of mutant #13 was destroyed. Only one amino acid is different between the two mutants (mutant #10, R47L/F87V/L188Q; mutant #13, R47L/L86I/F87V/L188Q). At present, the structural differences between the two mutants are not known.

Several mutant forms of CYP102A1 were found to metabolize various drugs of human P450 enzymes (Yun et al., 2007 and references therein). Structural rationalization to the mutations of CYP102A1 should be useful to make desired activities of the enzyme. In addition to the directed evolution, the use of rational design for predicting protein structure and calculating the precise molecular interactions between the substrate and active site of the enzyme can be successfully applied to the engineering of CYP102A1 to a specific medium chain \( p \)-nitrophenoxycarboxylic acid (Li et al., 2001). More recently, computational methods combined with experimental techniques including molecular dynamics simulations, resonance Raman, and UV-VIS spectroscopy, as well as coupling efficiency and substrate-binding experiments, could be successfully applied to the engineering of CYP102A1 to metabolize human CYP2D6 substrates, 3,4-methylenedioxyamphetamine and dextromethorphan (Stjernschantz et al., 2008).

The production of piceatannol by chemical synthesis has been reported (Kim et al., 2008b). However, an alternative to chemical synthesis of piceatannol is to use CYP102A1 enzymes to generate the metabolites of resveratrol. From the viewpoint of “White Biotechnology” as part of a sustainable “Green Biotechnology” (Stottmeister et al., 2005), the production of piceatannol via an enzyme reaction should be more effective and cleaner.

In summary, this work with a set of CYP102A1 mutants and trans-resveratrol, a human P450 substrate, revealed that bacterial CYP102A1 enzymes catalyze the same reaction as human CYP1A2. The oxidation of resveratrol, a human CYP1A2 substrate, is catalyzed by wild-type and some mutants of CYP102A1. One major hydroxylated product, piceatannol, was produced as a result of a hydroxylation reaction. Other hydroxylated products were not produced. Piceatannol formation was confirmed by HPLC and GC-MS by comparing the metabolite with the authentic piceatannol compound. Thus, the CYP102A1 mutants efficiently produce piceatannol, an authentic human metabolite of resveratrol.

### References


<p>| TABLE 2 | Kinetic parameters of piceatannol formation by CYP102A1 mutants |</p>
<table>
<thead>
<tr>
<th>P450 BM3</th>
<th>( k_{cat} )</th>
<th>( K_m )</th>
<th>( k_{cat}/K_m )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutant #9</td>
<td>0.20 ± 0.02</td>
<td>66 ± 14</td>
<td>0.0030 ± 0.0007</td>
</tr>
<tr>
<td>Mutant #10</td>
<td>1.1 ± 0.1</td>
<td>30 ± 15</td>
<td>0.037 ± 0.016</td>
</tr>
<tr>
<td>Mutant #11</td>
<td>0.12 ± 0.01</td>
<td>2.7 ± 0.7</td>
<td>0.044 ± 0.012</td>
</tr>
<tr>
<td>Mutant #12</td>
<td>0.13 ± 0.01</td>
<td>54 ± 11</td>
<td>0.0024 ± 0.0005</td>
</tr>
<tr>
<td>Mutant #13</td>
<td>6.7 ± 0.3</td>
<td>15 ± 3</td>
<td>0.45 ± 0.09</td>
</tr>
<tr>
<td>Mutant #14</td>
<td>0.58 ± 0.04</td>
<td>13 ± 3</td>
<td>0.046 ± 0.011</td>
</tr>
<tr>
<td>Mutant #15</td>
<td>0.54 ± 0.02</td>
<td>16 ± 2</td>
<td>0.038 ± 0.005</td>
</tr>
</tbody>
</table>

Dong-Hyun Kim, Taeho Ahn, Heungs-Chae Jung, Jae-Gyu Pan, and Chul-Ho Yun


Microbiology Research Center, Chonnam National University, Gwangju, Republic of Korea (T.A.); and Systems Biology Research Center, Chonnam National University, Gwangju, Republic of Korea (D.-H.K., C.-H.Y.); Department of Biochemistry, College of Veterinary Medicine, Chonnam National University, Gwangju, Republic of Korea (D.-H.K., C.-H.Y.); Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea (H.-C.J., J.-G.P.)


Address correspondence to: Prof. Chul-Ho Yun, School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea. E-mail: chyun@jnu.ac.kr